Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth)2026 total operating expense guidance of US$330 – US$335 millionInvestor Day will be webcast today starting at 10:00 am EST (16:...
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rar...
The market environment now appears more favourable for small caps (solid growth prospects, consistent valuations) and the rebound seen in this asset class in 2025 could continue into 2026. After a stellar performance of 32.2% (+16.3 points vs MSCI Europe Smallcaps) from our ODDO BHF European Nextcap list in 2025, we are revising our H1 2026 Nextcap top pick list, which now includes: Comet, Corbion, Equasens, Jacquet Metals, Jost-Werke, PVA Tepla, Rosenbauer, Steyr Motors, Thermador Groupe and Wa...
L’environnement de marché semble à présent plus porteur pour les small caps (perspectives de croissance solides, valorisations cohérentes) et 2026 pourrait prolonger le rebond observé en 2025 sur cette classe d’actifs. Après une belle performance de 32.2% (+16.3 pt vs MSCI Europe Small Cap) en 2025 de notre liste ODDO BHF European Nextcap, nous revoyons notre liste de convictions Nextcap S1 2026 qui comprend désormais : Comet, Corbion, Equasens, Jacquet Metals, Jost-Werke, PVA Tepla, Rosenbauer,...
In the context of the ODDO BHF Forum, we had the opportunity to get an update on management's short- and medium-term ambitions. The next few months are set to be transformative for Medincell, with 1/ the ramp-up in sales of Uzedy, 2/ the launch of Olanzapine LAI, considered by its partner Teva to be a blockbuster, and 3/ the entry into clinical trials of its first drug candidate from its partnership with Abbvie. These commercial, regulatory and clinical milestones will likely support the share p...
Dans le cadre du Forum ODDO BHF, nous avons eu l’occasion de revenir sur les ambitions à court et moyen termes du management. Aussi, les prochains mois de Medincell devraient être transformants avec 1/ la montée en puissance des ventes d’Uzedy, 2/ le lancement d’Olanzapine LAI considéré par son partenaire Teva comme un blockbuster et 3/ l’entrée en clinique de son 1er candidat médicament venant de son partenariat avec Abbvie. Ces milestones commerciaux, réglementaires et cliniques devraient perm...
Pharming Group reports preliminary 2025 revenues and announces Investor Day Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET). Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2...
BILAN SEMESTRIEL S2 DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC LA SOCIÉTÉ DE BOURSE GILBERT DUPONT BILAN SEMESTRIEL S2 DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC LA SOCIÉTÉ DE BOURSE GILBERT DUPONT Villers-lès-Nancy, 7 janvier 2026, 19h00 CET – Equasens (isin : FR0012882389 – Mnémo : EQS), leader des solutions numériques pour les professionnels de santé, fait état du contrat de liquidité confié à la Société de Bourse Gilbert Dupont, jusqu’au 31 décembre 2025 inclus. Au titre du contrat de liquidité confié par la société EQUASENS à la Société de Bourse Gilbert Dupont, à la date du 31 décembre 20...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.